Tuesday, July 11, 2023 Daily Archives

WuXi Bio plans ADC spin-off and $500m Hong Kong IPO

by and

CDMO WuXi Biologics has announced plans to spin-off its antibody-drug conjugate (ADC) operations with the goal of listing the division in an IPO on the Hong Kong Exchange that could raise $500 million. The subsidiary, known as WuXi XDC, is a joint venture between WuXi Biologics (60%) and WuXi STA (40%) that provides contract R&D and manufacturing for bioconjugates, including antibody drug conjugates (ADCs). WuXi STA offers chemical CDMO services, while WuXi Biologics is its biologic counterpart. With its focus…

July 11, 2023

Ardena and RiboPro ink RNA deal

by

Ardena will combine its lipid nanoparticles formulations with RibPro’s mRNA tech to improve accessibility of RNA-based treatments. Under the terms of the deal, of which financials have not been divulged, contract development manufacturing organization (CDMO) Ardena has partnered with Dutch messenger RNA (mRNA) firm RiboPro to address “a crucial skills gap in the industry.”   In addition to RiboPro’s portfolio of mRNA-related technologies, they will also provide experience in mRNA synthesis and encapsulation. In turn, both parties said the partnership will…

July 11, 2023